Other grades of this product :
| Beraprost sodium Basic information |
| Beraprost sodium Chemical Properties |
| Beraprost sodium Usage And Synthesis |
| Description | Beraprost sodium is a new, orally active antithrombotic epoprostenol analog introduced as a treatment for peripheral vascular disease, including Raynaud's syndrome and
Buerger's disease. The antiplatelet activity may be due to its elevation of cyclic AMP
in platelets which is achieved by activating adenylate cyclase in the platelet membrane,
followed by the inhibition ofCa++- influx and thromboxane A2 formation. | | Description | Beraprost is an analog of prostacyclin in which the unstable enol-ether has been replaced by a benzofuran ether function. This modification increases the plasma half-life from 30 seconds to several hours, and permits the compound to be taken orally. Doses of 20-100 μg in humans, given 1 to 3 times per day, have been demonstrated to improve clinical end points in diseases responsive to prostacyclin. Oral beraprost therapy improved the survival and pulmonary hemodynamics of patients with primary pulmonary hypertension. Beraprost inhibits platelet aggregation in healthy subjects and in diabetic patients at similar doses. | | Chemical Properties | White Solid | | Originator | Toray (Japan) | | Uses | Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral). | | Brand name | Dorner; Dorner;Procylin | | General Description | Beraprost sodium is an orally active prostacyclin analog. | | Biochem/physiol Actions | Beraprost sodium is used as a therapeutic agent for chronic artery obstructions or primary pulmonary hypertension. In individuals with coronary artery disease, beraprost sodium helps to reduce oxidative stress and developed forearm endothelium dependent vasodilation. |
| Beraprost sodium Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye